Press Releases Tharimmune, Inc.

Equities

THAR

US4327052001

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-24 pm EDT			5-day change	1st Jan Change
0.3049 ^USD	-6.87%		-15.54%	-40.10%

12:00am	Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	CI
12:00am	Certain Options of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tharimmune Announces 1-for-15 Reverse Stock Split	May. 23	AQ
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	Apr. 24	AQ
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics	Apr. 16	AQ
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024	Mar. 06	AQ
Tharimmune Announces 1-for-25 Reverse Stock Split	Nov. 20	AQ
Thinking about buying stock in PaxMedica, Applied Therapeutics, Tharimmune, Singular Genomics Systems, or BIOLASE?	Nov. 08	PR
Tharimmune : Submission of Matters to a Vote of Security Holders - Form 8-K	23-10-24	PU
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.	23-09-25	AQ
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis	23-09-11	AQ
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13	23-09-08	AQ
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023	23-08-09	AQ
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215	23-07-20	AQ
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics	23-07-10	AQ
Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers	23-07-06	AQ
Hillstream BioPharma : Non-Reliance on Previously Issued Financial Report - Form 8-K	23-05-23	PU
Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson	23-05-15	AQ
Hillstream BioPharma Announces Closing of Public Offering of Common Stock	23-05-02	AQ
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences	23-05-02	AQ
HILLSTREAM BIOPHARMA INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	23-05-01	AQ
Hillstream BioPharma Announces Pricing of Public Offering	23-04-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tharimmune, Inc.

Equities

THAR

US4327052001

Press Releases

Filters